瑞戈非尼治疗难治性结直肠癌患者时的1型骨钙素：TEXCAN和CORRECT试验的事后生物标志物分析
Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A Post Hoc Biomarker Analysis of the TEXCAN and CORRECT Trials.
作者信息
Vienot Angélique, Vernerey Dewi, Bouard Adeline, Klajer Elodie, Kim Stefano, Tournigand Christophe, Louvet Christophe, André Thierry, Rousseau Benoît, Wespiser Mylène, Spehner Laurie, Wang Ying A, Weispfenning Anke, Dochy Emmanuelle, Borg Christophe
机构信息
Department of Medical Oncology, University Hospital of Besançon, Besançon, France.
University of Franche Comté, EFS, INSERM, UMR RIGHT, Besançon, France.
出版信息
Cancer Res Commun. 2025 Feb 1;5(2):287-294. doi: 10.1158/2767-9764.CRC-24-0246.
STC1 is a protein secreted by intratumor endothelial cells in which plasma concentrations increase in patients with chemorefractory mCRC. Based on analyses of patients with refractory mCRC in the TEXCAN and CORRECT trials, we found that STC1 plasma levels had a prognostic role for OS, with high levels associated with poor outcome. A predictive role for baseline STC1 levels was pointed out for regorafenib efficacy.
STC1是一种由肿瘤内内皮细胞分泌的蛋白质，在化疗难治性转移性结直肠癌（mCRC）患者中血浆浓度会升高。基于对TEXCAN和CORRECT试验中难治性mCRC患者的分析，我们发现STC1血浆水平对总生存期（OS）具有预后作用，高水平与不良预后相关。有人指出基线STC1水平对瑞戈非尼疗效具有预测作用。
Zotero 插件